Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study

Ma, Huiyan; Xu, Xinxin; Clague, Jessica; Lu, Yani; Togawa, Kayo; Wang, Sophia S.; Clarke, Christina A.; Lee, Eunjung; Park, Hannah L.; Sullivan-Halley, Jane; Neuhausen, Susan L.; Bernstein, Leslie

doi:10.1186/s13058-016-0723-3

Breast Cancer Research

Table 5 Adjusted hazard ratios for the associations between strenuous recreational physical activity and invasive breast cancer subtypes among menopausal hormone therapy users

From: Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study

	Cases, no.	Strenuous RPA, h/wk/y			P _trend	P _{homogeneity of trends}
		≤0.50	0.51–3.50	≥3.51	P _trend	P _{homogeneity of trends}
		Adjusted HR (95 % CI)	Adjusted HR (95 % CI)	Adjusted HR (95 % CI)
TNBC (ER-/PR-/HER2-)
Long-term^a
Type of MHT use
E only	47	Referent	0.80 (0.43–1.48)	0.63 (0.23–1.71)	0.34	0.29
E + P	108	Referent	0.99 (0.64–1.52)	1.12 (0.61–2.08)	0.71
Duration of MHT use
<5 years	80	Referent	0.98 (0.60–1.62)	1.09 (0.55–2.19)	0.80	0.53
≥5 years	75	Referent	0.87 (0.53–1.42)	0.81 (0.37–1.75)	0.57
Cessation of MHT use
Former MHT use	24	Referent	1.00 (0.42–2.38)	0.81 (0.22–3.02)	0.77	0.81
Recent MHT use	131	Referent	0.91 (0.61–1.34)	0.98 (0.55–1.74)	0.92
Baseline^b
Type of MHT use
E only	47	Referent	0.93 (0.47–1.87)	0.89 (0.31–2.56)	0.80	0.60
E + P	108	Referent	0.98 (0.63–1.52)	0.58 (0.26–1.28)	0.20
Duration of MHT use
<5 years	80	Referent	1.00 (0.61–1.66)	0.46 (0.16–1.28)	0.17	0.40
≥5 years	75	Referent	0.93 (0.54–1.60)	0.90 (0.40–2.02)	0.76
Cessation of MHT use
Former MHT use	24	Referent	0.58 (0.20–1.72)	0.35 (0.05–2.64)	0.21	0.30
Recent MHT use	131	Referent	1.05 (0.70–1.56)	0.73 (0.37–1.44)	0.43
Luminal A-like (ER+ or PR+ plus HER2-)
Long-term^a
Type of MHT use
E only	375	Referent	1.00 (0.80–1.25)	0.84 (0.60–1.17)	0.31	0.75
E + P	931	Referent	0.89 (0.77–1.02)	0.90 (0.73–1.11)	0.32
Duration of MHT use
<5 years	580	Referent	0.81 (0.67–0.97)	0.90 (0.70–1.16)	0.41	0.89
≥5 years	726	Referent	1.01 (0.86–1.19)	0.86 (0.67–1.10)	0.26
Cessation of MHT use
Former MHT use	171	Referent	0.84 (0.61–1.16)	0.52 (0.30–0.89)	0.02	0.03
Recent MHT use	1135	Referent	0.93 (0.82–1.06)	0.95 (0.78–1.15)	0.59
Baseline^b
Type of MHT use
E only	375	Referent	0.82 (0.63–1.06)	0.94 (0.67–1.32)	0.49	0.65
E + P	931	Referent	0.96 (0.82–1.12)	0.98 (0.79–1.21)	0.75
Duration of MHT use
<5 years	580	Referent	0.91 (0.75–1.11)	0.86 (0.65–1.14)	0.24	0.29
≥5 years	726	Referent	0.92 (0.77–1.10)	1.05 (0.83–1.33)	0.83
Cessation of MHT use
Former MHT use	171	Referent	0.96 (0.67–1.36)	0.44 (0.22–0.87)	0.02	0.02
Recent MHT use	1135	Referent	0.92 (0.79–1.06)	1.05 (0.87–1.27)	0.84

Results are for 39,715 peri- and postmenopausal women who had ever used MHT with known information regarding type, duration and cessation of MHT use at baseline. HRs are from multivariable Cox proportional hazards regression models using age (in days) as the time metric and stratified by age (in years) with the adjustment for race, family history of breast cancer in first-degree relatives, combined age at first full-term pregnancy and parity variable, BMI at baseline, history of smoking, alcohol intake during the past year of baseline, screening mammogram in the past 2 years of baseline, history of a breast biopsy, and a corresponding moderate RPA variable; additionally, type of MHT, duration of MHT, and cessation of MHT were mutually adjusted
Abbreviations: BMI body mass index, CI confidence interval, E estrogen, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, h/wk/y hour/week/year, MHT menopausal hormone therapy, P progestin, PR progesterone receptor, RPA recreational physical activity, TNBC triple negative breast cancer
^aRPA from high school till age 54 or age at cohort entry, whichever was younger
^bRPA during the 3 years prior to baseline

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com